During the past decade, Centre de radiothérapie et d'Oncologie médicale de l'Essonne conducted 3 clinical trials. In the 10-year time frame, 3 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Centre de radiothérapie et d'Oncologie médicale de l'Essonne" are "Metastatic Castrate Sensitive Prostate Cancer" (1 trials), "Metastatic Prostate Cancer" (1 trials) and "Urothelial Cancer" (1 trials). Many other conditions were trialed in "Centre de radiothérapie et d'Oncologie médicale de l'Essonne" in a lesser frequency.

Most popular intervention types in "Centre de radiothérapie et d'Oncologie médicale de l'Essonne" are "Drug" (2 trials), "Device" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Abiraterone acetate (AA)" (1 trials), "Docetaxel" (1 trials), "Erdafitinib" (1 trials), "Fibroblast Growth Factor Receptor inhibitor Clinical Trial Assay (FGFRi CTA)" (1 trials) and "Niraparib" (1 trials). Other intervention names were less common.

The vast majority of trials in "Centre de radiothérapie et d'Oncologie médicale de l'Essonne" are 2 trials for "Male" genders and 1 trials for "All" genders.

Currently, there are NaN active trials in "Centre de radiothérapie et d'Oncologie médicale de l'Essonne". undefined are not yet recruiting, 2 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in Centre de radiothérapie et d'Oncologie médicale de l'Essonne, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Centre de radiothérapie et d'Oncologie médicale de l'Essonne, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".